Infectious Disease & Vaccines

LIVE October 26th, 2021 at 11:00 AM ET
Experts will discuss recent advances in screening strategies to more efficiently identify therapeutic candidates for infectious diseases such as schistosomiasis and COVID-19.

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

Researchers employ CRISPR technology in a variety of creative ways to control the spread of vector-borne illnesses.

Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.

Through research experience, scientists develop a strong sense of resiliency. The COVID-19 pandemic put that resiliency to the test, and now as vaccination rates increase and communities begin to open up, it’s time to take a breath.

Experiments in ferrets show that a prophylactic spray cuts SARS-CoV-2 replication by more than 90 percent by priming the innate immune system.

Vaccine development for infectious diseases gives rise to new vaccine approaches and accelerated development and approval timelines.

Researchers are conducting the first long-term perspective study to understand the immune response to COVID-19 long after initial infection.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.